Authors

Latest:

Q&A: Final Questions on Glioblastoma and Neuroimaging

Nathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.

Avyakta Kallam, MBBS

Latest:

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Jacob J. Adashek, DO

Latest:

Dr. Adashek on Targeting Molecular Alterations to Treat Multiple Tumor Types

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.

Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center

Latest:

ASCO GI 2021: MRD Detection With ctDNA From Assays

Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.

Johannes Zakrzewski, MD

Latest:

Dr. Zakrzewski on Investigation of IT848 Nanotherapy in Hematologic Malignancies

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Alicia Morgans, MD, MPH

Latest:

Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate Cancer

Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.

Lillian L Siu, MD, FRCPC

Latest:

Dr Siu on the Rationale for Combining Petosemtamab With Pembrolizumab in HNSCC

Lillian L. Siu, MD, FRCPC, discusses the background for evaluating first-line petosemtamab plus pembrolizumab in recurrent/metastatic PD-L1+ HNSCC.

Richard J. Bleicher, MD, FACS

Latest:

Fellows on Film: How To Market Yourself for a Fellowship

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.

Stephen Liu, MD

Latest:

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Drs Park and Liu discuss the use of amivantamab plus lazertinib in EGFR-mutated non–small cell lung cancer.

Lipika Goyal, MD

Latest:

FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Matthew Lunning, DO, FACP

Latest:

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

Alex Duval, MD, PhD

Latest:

Dr. Duval on the Use of MSI-H as a Biomarker of Response in Patients With Cancer

Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.

Cortney Eakin, MD

Latest:

Dr. Eakin on Racial Disparities in Uterine Cancer

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

Sasha Stanton, MD

Latest:

Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast Cancer

Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.

Morgan Bayer

Latest:

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

Christopher Morse, MD

Latest:

Taking Action to Individualize Ovarian Cancer Care: Key Takeaways

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.

April Rose, MD

Latest:

Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

Joshua Strauss, MD

Latest:

Dr. Strauss on Future Research Directions in SCLC

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Sanjeet Singh Dadwal, MD

Latest:

Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCT

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Lindsay Fischer

Latest:

Fostering Interactions That Heal

The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.